Ramosetron
Ramosetron (INN) is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting.[1] Ramosetron is also indicated for a treatment of "diarrhea-predominant irritable bowel syndrome in male and women".[2] In India it is marketed under the brand name of Ibset.
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | By mouth (ODT), IV |
ATC code |
|
Pharmacokinetic data | |
Elimination half-life | 5.8 hours |
Identifiers | |
IUPAC name
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H17N3O |
Molar mass | 279.343 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
NY (what is this?) (verify) |
It is only licensed for use in Japan and selected Southeast Asian countries. In Japan it is sold under the trade name Irribow.[3][4] and in India as Ibset . 'Elsewhere it is commonly sold under the trade name Nasea and in India as Nozia (150 μg/mL injection & 100 μg oral tablet).[5]
References
- Fujii Y, Saitoh Y, Tanaka H, Toyooka H (February 2000). "Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery". Anesth. Analg. 90 (2): 472–5. doi:10.1097/00000539-200002000-00043. PMID 10648342.
- "2008 News Releases - Astellas Pharma Inc". www.astellas.com.
- Summary in Japanese. Retrieved on September 4, 2012.
- "2013 News Releases | Astellas Pharma Inc". www.astellas.com. Retrieved 2018-04-06.
- Abridged prescribing information — Nasea (MIMS Philippines). Retrieved on June 13, 2008.
Drugs for functional gastrointestinal disorders (A03) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drugs for functional bowel disorders |
| ||||||||||||
Belladonna and derivatives (antimuscarinics) |
| ||||||||||||
Propulsives |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.